Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 8)

 atrial fibrillation (part 8)

Karlsson and coworkers randomized 44 patients to di-sopyramide and 46 to placebo in a double-blind multicentre study. The most common diagnosis in both groups was lone AF. After one year, 30% of patients in the placebo group and 54% in the disopyramide group were still in sinus rhythm (P<0.01). Five patients in the disopyramide group (11%) and two in the placebo group were withdrawn because of side effects.
Although in the present study several side effects were associated with each agent, only four patients discontinued therapy due to adverse effects. We did not observe life-threatening ventricular proarrhythmia, which was probably connected with restricted, broad exclusion criteria, small dose of antiarrhythmic drugs and a small number of patients. As we expected, the lowest heart rate was observed in sotalol-treated patients on 24 h Holter ECG monitoring.

The choice of prophylactic antiarrhythmic drug must take into consideration effectiveness and safety of therapy. The sequential use of different types of antiarrhythmic drugs may improve arrhythmia prognosis in chronic AF after successful electrical cardioversion . The rationale for serial treatment is that the arrhythmogenic mechanism may vary among patients, leading to different responses to a specific drug.
Find most trusted pharmacy that will give you cialis super active online pharmacy click here in the amounts required without any need for a prescription. You will see that shopping with a place you can already trust over and over again is very affordable and always nice.

This entry was posted in Cardiology and tagged Antiarrhythmic therapy, Cardioversion, Chronic atrial fibrillation.